{"schema_version":"alpha-company-profile-public-v2","slug":"acrivon-therapeutics-inc","canonical_url":"https://registry.alpha.ac/companies/acrivon-therapeutics-inc","published_on":"2026-09-12T21:32:20.364321+00:00","last_reviewed_on":"2026-09-12T21:32:20.364321+00:00","identity":{"legal_name":"Acrivon Therapeutics, Inc.","display_name":"Acrivon Therapeutics, Inc.","headline":"Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments.","description":"Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific Onco","ten_second_view":"This Company Profile publishes only Alpha's canonical identity and evidence-backed public leadership records. Unavailable fields are not inferred.","legal_form":"Not publicly asserted","incorporation":"Not publicly asserted","headquarters":"US","headquarters_address":{"locality":"Not publicly asserted","region":null,"country":"US"},"operating_presence":["US"],"website":"","cik":"0001781174","logo":"https://cdn.brandfetch.io/ticker/acrv/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","logo_source":"brandfetch","profile_mark":{"src":"https://cdn.brandfetch.io/ticker/acrv/theme/dark/fallback/404/type/logo?c=1idgAB6rG5KFT5I7q5w","alt":"Acrivon Therapeutics, Inc. logo","width":256,"height":256,"source":"brandfetch"}},"entity_status":{"ownership_type":"unknown","listing_status":"listed","label":"Public listing published","explanation":"The canonical public record includes at least one active security listing.","source_id":"alpha-canonical-company-record","reviewed_on":"2026-09-12T21:32:20.364321+00:00"},"security_listings":[{"ticker":"ACRV","exchange":"NASDAQ","exchange_display":"NASDAQ","mic":"XNAS","currency":"Unavailable","security_type":"equity","listing_status":"active","is_primary":true,"source_id":"alpha-canonical-company-record"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market data is not published in this Company Profile."},"profile_tags":["Canonical identity","Public leadership"],"trust_summary":"Canonical identity published; broader company intelligence is not asserted.","facts":[{"label":"Legal name","value":"Acrivon Therapeutics, Inc.","source_id":"alpha-canonical-company-record"},{"label":"Country","value":"US","source_id":"alpha-canonical-company-record"},{"label":"Sector","value":"Healthcare","source_id":"alpha-canonical-company-record"},{"label":"Industry","value":"Biotechnology","source_id":"alpha-canonical-company-record"}],"operating_model":{"eyebrow":"Operating record","title":"Published operating structure","units":[]},"governance":{"summary":"Only current, confirmed leadership roles with public evidence are included in the canonical projection.","boundary":"Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","disclosures":[]},"alpha_opinion":{"status":"Not published","label":"No Alpha opinion published","explanation":"This identity record is not an Alpha rating, score, or investment opinion."},"report":{"status":"Not published","label":"No governed report published","explanation":"No governed company report is attached to this profile.","href":null},"actions":[],"related_records":[],"evidence":[{"id":"alpha-canonical-company-record","label":"Alpha canonical company public projection","href":"/api/public/companies/acrivon-therapeutics-inc","source_type":"canonical_identity","supports":["Company identity","Published leadership","Entity status boundary"],"status":"published","reviewed_on":"2026-09-12T21:32:20.364321+00:00"}],"permissions":[{"label":"Public retrieval","allowed":true},{"label":"Agent retrieval","allowed":true},{"label":"Redistribution","allowed":false},{"label":"Model training","allowed":false},{"label":"Relationship pathfinding","allowed":false},{"label":"Direct contact","allowed":false}],"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"trust":{"schema_version":"alpha-profile-trust-v1","verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":13,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"aggregation":{"schema_version":"alpha-claim-aggregation-v1","published_claim_count":13,"under_review_claim_count":1,"owner_supplied_claim_count":0,"evidence_record_count":2,"distinct_source_count":2,"conflicts":[],"conflict_count":0,"headline_conflict_count":0,"internal_review_conflict_count":0,"contradiction_types":[],"headline_conflict_types":[],"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":13,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed."},"coverage":{"schema_version":"alpha-coverage-metric-v1","published_claims":13,"corroborated_claims":0,"sources":2,"distinct_sources":2,"role_claims":0,"last_reviewed_at":"2026-09-12T21:32:20.364321+00:00","observed_at":"2026-09-12T21:32:20.364321+00:00","freshness_days":0}},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"}},"projection":{"schema_version":"alpha-profile-projection-v5","entity":{"kind":"company","slug":"acrivon-therapeutics-inc","canonical_url":"https://registry.alpha.ac/companies/acrivon-therapeutics-inc"},"publication":{"published_at":"2026-09-12T21:32:20.364321+00:00","last_reviewed_at":"2026-09-12T21:32:20.364321+00:00","as_of":"2026-09-12T21:32:20.364321+00:00"},"representations":{"html":{"href":"https://registry.alpha.ac/companies/acrivon-therapeutics-inc","media_type":"text/html"},"json":{"href":"https://registry.alpha.ac/api/public/companies/acrivon-therapeutics-inc","media_type":"application/json"},"markdown":{"href":"https://registry.alpha.ac/companies/acrivon-therapeutics-inc.md","media_type":"text/markdown"},"structured_data":{"embedded":true,"media_type":"application/ld+json"},"share_image":null},"permissions":{"public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false}},"canonical_profile":{"schema_version":"alpha-company-profile-public-v1","slug":"acrivon-therapeutics-inc","canonical_url":"https://registry.alpha.ac/companies/acrivon-therapeutics-inc","as_of":"2026-09-12T21:32:20.364321+00:00","last_reviewed_at":"2026-09-12T21:32:20.364321+00:00","identity":{"legal_name":"Acrivon Therapeutics, Inc.","display_name":"Acrivon Therapeutics, Inc.","description":"Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific Onco","jurisdiction":null,"country":"US","sector":"Healthcare","industry":"Biotechnology","website":null,"website_provenance":null,"logo_url":null,"logo_media":null,"status":"active","cik":"0001781174","entity_subtype":null,"legal_entity_status":null},"security_listings":[{"mic":"XNAS","ticker":"ACRV","currency":null,"exchange":"NASDAQ","sort_key":0,"valid_to":null,"confidence":0.95,"is_primary":true,"listing_id":"b0ba4fb6-b084-48b7-9f9f-534e070ab627","source_url":"https://www.sec.gov/files/company_tickers_exchange.json","valid_from":null,"observed_at":"2026-07-11T00:28:32+00:00","source_name":"sec_company_tickers_exchange","source_tier":1,"exchange_name":"NASDAQ","security_type":"equity","listing_status":"active","last_checked_at":"2026-09-02T01:48:40.989053+00:00"}],"market_data":{"availability":"unavailable","endpoint":null,"source_label":null,"explanation":"Market observations are unpublished. Listing identity remains available from the governed source set."},"index_memberships":[],"index_membership_history":[],"index_membership_contract":{"schema_version":"alpha-index-membership-public-v1","as_of_date":"2026-09-13","tracked_universe_complete":false,"permissions":{"public_retrieval":true,"agent_retrieval":false,"redistribution":false,"model_training":false},"limitations":["Only source-backed memberships with an explicit public redistribution basis are returned.","Absence from Alpha tracked indices does not establish absence from every market index.","Provider announcements and effective membership are represented as distinct states.","Alpha AI 100 is not published as a current public index membership."]},"leadership":{"board":[{"person_slug":"charles-baum-m-d-ph-d","display_name":"Charles Baum, M.D., Ph.D.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2023-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","source_url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-25","last_checked_at":"2026-04-24T20:10:02.508+00:00"},"headshot_url":null},{"person_slug":"derek-dirocco-ph-d","display_name":"Derek DiRocco, Ph.D.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2021-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","source_url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-25","last_checked_at":"2026-04-24T20:10:02.508+00:00"},"headshot_url":null},{"person_slug":"ivana-magovevic-liebisch-ph-d-j-d","display_name":"Ivana Magovevic-Liebisch, Ph.D., J.D.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","source_url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-25","last_checked_at":"2026-04-24T20:10:02.508+00:00"},"headshot_url":null},{"person_slug":"kristina-masson-ph-d-m-b-a","display_name":"Kristina Masson, Ph.D., M.B.A.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2018-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","source_url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-25","last_checked_at":"2026-04-24T20:10:02.508+00:00"},"headshot_url":null},{"person_slug":"michael-tomsicek-m-b-a","display_name":"Michael Tomsicek, M.B.A.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2022-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","source_url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-25","last_checked_at":"2026-04-24T20:10:02.508+00:00"},"headshot_url":null},{"person_slug":"peter-blume-jensen-m-d-ph-d","display_name":"Peter Blume-Jensen, M.D., Ph.D.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2018-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","source_url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-25","last_checked_at":"2026-04-24T20:10:02.508+00:00"},"headshot_url":null},{"person_slug":"santhosh-palani-ph-d-c-f-a","display_name":"Santhosh Palani, Ph.D., CFA","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2024-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","source_url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-25","last_checked_at":"2026-04-24T20:10:02.508+00:00"},"headshot_url":null},{"person_slug":"sharon-shacham-ph-d-m-b-a","display_name":"Sharon Shacham, Ph.D., M.B.A.","role_category":"director","title":"Director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null,"verification_status":"unconfirmed","confidence":0.85,"evidence":{"document_title":"Acrivon Therapeutics, Inc. DEF 14A 2025-04-25","source_url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025058352/acrv-20250424.htm","source_type":"sec_proxy","published_at":null,"effective_date":"2025-04-25","last_checked_at":"2026-04-24T20:10:02.508+00:00"},"headshot_url":null}],"executives":[],"coverage":{"schema_version":"alpha-leadership-coverage-v1","board_roster_scope":"def_14a_current_directors","executive_roster_scope":"NOT_ASSERTED","neo_set_status":"NOT_ASSERTED","board_roster_complete":false,"neo_set_complete":false,"notes":["Empty executives is NOT_ASSERTED, not a complete named-executive-officer set.","Form 4 occupancy is not a DEF 14A board.","Unconfirmed current sec_proxy DEF 14A directors may project. Confirmed is not required.","Unconfirmed current executives with first-party issuer evidence (source_url + effective date) may project.","Company-page directors do not require people.public_profile_enabled.","Completeness compares the latest first-party roster with the public projection; a source older than 180 days is STALE.","Do not remap HONA to HON 0000773840. Do not merge XOM 0000034088 with 0002115436.","Person match is projection-only. Name-only Person merges are forbidden."],"completeness":{"reasons":["NO_LEADERSHIP_SOURCE"],"board_completeness":"NOT_REVIEWED","completeness_schema":"alpha-leadership-completeness-v1","executive_team_completeness":"NOT_REVIEWED"},"parser_bleed_excluded":true,"former_titles_excluded":true,"identity_merge_forbidden":true,"form4_occupancy_is_not_board":true}},"permissions":{"classification":"open_public_projection","public_retrieval":true,"agent_retrieval":true,"redistribution":false,"model_training":false,"relationship_pathfinding":false,"direct_contact":false},"limitations":["Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."],"structured_data":{"@context":["https://schema.org",{"alpha":"https://alpha.ac/ns/","indexMembership":"alpha:indexMembership","indexProvider":"alpha:indexProvider","indexMembershipStatus":"alpha:indexMembershipStatus","indexEffectiveDate":"alpha:indexEffectiveDate","indexAnnouncementDate":"alpha:indexAnnouncementDate","indexRemovalDate":"alpha:indexRemovalDate","lastVerifiedAt":"alpha:lastVerifiedAt","verificationStatus":"alpha:verificationStatus","evidence":"alpha:evidence"}],"@type":"ProfilePage","@id":"https://registry.alpha.ac/companies/acrivon-therapeutics-inc#profile","url":"https://registry.alpha.ac/companies/acrivon-therapeutics-inc","dateModified":"2026-09-12T21:32:20.364321+00:00","mainEntity":{"@type":"Organization","@id":"https://registry.alpha.ac/companies/acrivon-therapeutics-inc#organization","legalName":"Acrivon Therapeutics, Inc.","name":"Acrivon Therapeutics, Inc.","description":"Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific Onco","url":"https://registry.alpha.ac/companies/acrivon-therapeutics-inc","addressCountry":"US","indexMembership":[],"member":[{"@type":"OrganizationRole","roleName":"Director","startDate":"2023-01-01","member":{"@type":"Person","name":"Charles Baum, M.D., Ph.D.","url":"https://registry.alpha.ac/people/charles-baum-m-d-ph-d"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2021-01-01","member":{"@type":"Person","name":"Derek DiRocco, Ph.D.","url":"https://registry.alpha.ac/people/derek-dirocco-ph-d"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"Ivana Magovevic-Liebisch, Ph.D., J.D.","url":"https://registry.alpha.ac/people/ivana-magovevic-liebisch-ph-d-j-d"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2018-01-01","member":{"@type":"Person","name":"Kristina Masson, Ph.D., M.B.A.","url":"https://registry.alpha.ac/people/kristina-masson-ph-d-m-b-a"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2022-01-01","member":{"@type":"Person","name":"Michael Tomsicek, M.B.A.","url":"https://registry.alpha.ac/people/michael-tomsicek-m-b-a"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2018-01-01","member":{"@type":"Person","name":"Peter Blume-Jensen, M.D., Ph.D.","url":"https://registry.alpha.ac/people/peter-blume-jensen-m-d-ph-d"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2024-01-01","member":{"@type":"Person","name":"Santhosh Palani, Ph.D., CFA","url":"https://registry.alpha.ac/people/santhosh-palani-ph-d-c-f-a"}},{"@type":"OrganizationRole","roleName":"Director","startDate":"2020-01-01","member":{"@type":"Person","name":"Sharon Shacham, Ph.D., M.B.A.","url":"https://registry.alpha.ac/people/sharon-shacham-ph-d-m-b-a"}}]},"mainEntityOfPage":"https://registry.alpha.ac/companies/acrivon-therapeutics-inc"}},"canonical_source":"aegis_canonical"}